Latest News

(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included a kidney cancer session and a presentation by Dr. Jose Karam discussing updates to the new AUA guidelines for the evaluation and management of clinically localized sporadic renal masses.1,2 Dr. Karam noted that the methodology for this guideline is comparable to previous AUA guidelines, including […]

(UroToday.com) The Society of Urologic Oncology (SUO) annual winter meeting included the annual Huggins Medal Award lecture with the 2021 recipient being Dr. Curtis Pettaway from the MD Anderson Cancer Center. Dr. Pettaway completed his BA in 1978 at Millersville University (Millersville, PA) followed by his medical degree in 1983 at the Temple University School of […]

In 2021-2022, many more men globally will receive a potent AR inhibitor in either the metastatic hormone sensitive prostate cancer (mHSPC), non-metastatic castration resistant prostate cancer (nmCRPC), or mCRPC settings, with improved long term outcomes based on multiple positive phase 3 trials of abiraterone, enzalutamide, apalutamide, and darolutamide. This new form of maximal or combined […]

(UroToday.com) The Society of Urologic Oncology (SUO) 2021 annual meeting in Orlando, FL hosted a State of the Art Lecture by Dr. Phillip Abbosh discussing the current state of urine liquid biopsy molecular markers in the bladder cancer disease space.

(UroToday.com) The Society of Urologic Oncology (SUO) 2021 annual winter meeting included a prostate cancer session and a presentation by Dr. Andrew Armstrong discussing a post-hoc analysis of the ARCHES trial assessing the extended efficacy of enzalutamide plus ADT on oligometastatic hormone-sensitive prostate cancer. In ARCHES, enzalutamide + ADT reduced the risk of radiographic progression and […]

(UroToday.com) The Society of Urologic Oncology (SUO) 2021 annual meeting in Orlando, FL included a comprehensive overview by Dr. Thomas Hope of “Integrating Imaging into Prostate Cancer Care”, specifically with regards to the diagnostic role of Prostate Specific Membrane Antigen (PSMA)-based positron emission tomography (PET) imaging in the different phases of prostate cancer management.

Because the reports in the literature of radiologic investigations for upper tract urothelial cancer (UTUC) are limited by the number of patients, and included patients with different pathologies, we aimed to study the overall accuracy of computed tomography (CT) in the diagnosis of UTUC and their accuracy on predicting tumor location.

Metastatic renal cell carcinoma can occur synchronously or metachronously. We characterized the time from diagnosis to systematic therapy as a categorical variable to analyze its effect on the overall survival and first-line treatment efficacy of metastatic renal cell carcinoma patients.

The incidence of testicular germ cell tumors (TGCT) is increasing steadily in the United States, particularly among Latinos. TGCT is thought to be initiated in utero and exposure to endocrine-disrupting chemicals, suspected contributors to TGCT pathogenesis, during this critical developmental period may contribute to the rise.

Renal cell carcinoma (RCC) is an aggressive genitourinary malignancy which has been associated with a poor prognosis, particularly in patients with metastasis, its major subtypes being clear cell RCC (ccRCC), papillary PCC (pRCC) and chromophobe RCC (chRCC).